Debunking Decentralized Trials: Sharing Breakthroughs and Deal Breakers
Jane E. Myles, MS
Head, Operational Intelligence and Innovation
Genentech, A Member of the Roche Group, United States
In this forum, a panel of experts will share their experience on the breakthroughs -what really works, and the deal breakers -what’s not working yet or was harder than expected. Our aim is to debunk the decentralized trial hype and share lessons learned. The forum will include perspectives from a sponsor, a decentralized trial vendor, a 'site' and if possible, a patient who has participated in a decentralized trial.
Learning Objective : Discuss key learnings about what's working well and what's not working well yet in decentralized trials; Identify if there any deal breakers to use them at this time;·Discuss your experiences on design and implementation of decentralized trials; Describe the patient and site perspective on participation in decentralized trials.
Leonard Sacks, MD
Associate Director for Clinical Methodology, Office of Medical Policy, CDER
FDA, United States
Komathi Stem, MS
Founder and Chief Executive Officer
monARC Bionetworks , United States
Jennifer C Goldsack, MBA
Senior Project Manager
Clinical Trials Transformation Initiative (CTTI), United States